melatonin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1672 73-31-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • melatonin
  • melatol
  • melatonine
  • circadin
A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.
  • Molecular weight: 232.28
  • Formula: C13H16N2O2
  • CLOGP: 1.03
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 54.12
  • ALOGS: -3.21
  • ROTB: 4

Drug dosage:

DoseUnitRoute
2 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.36 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 12 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.39 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Somnolence 434.34 43.84 104 379 23381 2334221
Pneumonia aspiration 430.34 43.84 76 407 3666 2353936
Coma 380.96 43.84 79 404 8977 2348625
Completed suicide 366.08 43.84 89 394 20945 2336657
Gastrooesophageal reflux disease 351.28 43.84 74 409 9021 2348581
Toxicity to various agents 203.68 43.84 62 421 32692 2324910
Intentional overdose 190.20 43.84 47 436 11274 2346328
Suicide attempt 121.58 43.84 33 450 11249 2346353
Intentional self-injury 78.27 43.84 19 464 4108 2353494
Tachycardia 71.78 43.84 24 459 16385 2341217
Seizure 62.41 43.84 24 459 24442 2333160
Cardio-respiratory arrest 58.98 43.84 18 465 9128 2348474
Insomnia 54.18 43.84 22 461 25765 2331837
Depressed level of consciousness 49.14 43.84 15 468 7589 2350013
Headache 45.38 43.84 28 455 80151 2277451
Confusional state 45.10 43.84 19 464 24325 2333277
Cestode infection 45.05 43.84 5 478 3 2357599

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Choreoathetosis 107.40 53.21 15 249 158 1746359
Completed suicide 100.47 53.21 30 234 16282 1730235
Agitation 70.68 53.21 21 243 11005 1735512
Toxicity to various agents 61.18 53.21 24 240 29117 1717400
Drug interaction 58.56 53.21 23 241 27935 1718582

Pharmacologic Action:

SourceCodeDescription
ATC N05CH01 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Melatonin receptor agonists
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:35488 central nervous system depressant
CHEBI has role CHEBI:50847 immunological adjuvant
MeSH PA D000975 Antioxidants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D020011 Protective Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Disorders of initiating and maintaining sleep indication 194437008
Alcoholism contraindication 7200002
Psoriasis contraindication 9014002 DOID:8893
Poisoning by digitalis glycoside contraindication 12876009
Constipation contraindication 14760008 DOID:2089
Sarcoidosis contraindication 31541009 DOID:11335
Depressive disorder contraindication 35489007
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Schizophrenia contraindication 58214004 DOID:5419
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Poisoning by acetaminophen contraindication 70273001
Hypercalciuria contraindication 71938000
Autoimmune disease contraindication 85828009
Kidney disease contraindication 90708001 DOID:557
Eosinophilia myalgia syndrome contraindication 95416007 DOID:998
Kidney stone contraindication 95570007
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.29 acidic
pKa2 13.99 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Melatonin receptor type 1B GPCR AGONIST EC50 9.70 WOMBAT-PK IUPHAR
Melatonin receptor type 1A GPCR AGONIST EC50 9.40 WOMBAT-PK IUPHAR
5-hydroxytryptamine receptor 2B GPCR ANTAGONIST Ki 5.20 IUPHAR
Nuclear receptor ROR-alpha Nuclear hormone receptor EC50 9 WOMBAT-PK
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme Ki 7.56 CHEMBL
Melatonin receptor GPCR Ki 9.75 CHEMBL
Melatonin receptor type 1B GPCR Ki 9.15 CHEMBL

External reference:

IDSource
4021324 VUID
N0000148757 NUI
C0025219 UMLSCUI
116523008 SNOMEDCT_US
5609 MMSL
6711 RXNORM
41199001 SNOMEDCT_US
5037 MMSL
d04058 MMSL
4021324 VANDF
005039 NDDF
896 PUBCHEM_CID
CHEBI:16796 CHEBI
CHEMBL45 ChEMBL_ID
DB01065 DRUGBANK_ID
JL5DK93RCL UNII
ML1 PDB_CHEM_ID
D008550 MESH_DESCRIPTOR_UI
224 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Viatrexx-Male Plus HUMAN PRESCRIPTION DRUG LABEL 5 73069-320 INJECTION 201 [kp_C] INTRAVENOUS unapproved drug other 11 sections
Viatrexx-Neuro 3 HUMAN PRESCRIPTION DRUG LABEL 15 73069-373 INJECTION 201 [kp_C] INTRAVENOUS unapproved drug other 11 sections
Viatrexx-Neuro HUMAN PRESCRIPTION DRUG LABEL 4 73069-375 INJECTION 201 [kp_C] INTRAVENOUS unapproved drug other 11 sections